• Johnson & Johnson announced early Phase 1 results showing sustained reductions in a prostate cancer marker with pasritamig plus JNJ-9401.
• Results were presented at the Society for Immunotherapy of Cancer’s 2026 annual meeting.
• No serious treatment-related side effects were reported at the recommended regimen; findings suggest potential for outpatient dosing every six weeks.
• The combination is being evaluated in the ongoing Phase 3 KLK2-comPAS trial for metastatic castration-resistant prostate cancer.
• Early findings at the recommended regimen involved 15 patients; larger studies are needed to establish clinical benefit and safety.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611081100PR_NEWS_USPR_____NY91870) on November 08, 2026, and is solely responsible for the information contained therein.